

# SOPHiA DDM™ Integrated Access Mode

Making accurate NGS analysis accessible to every lab



## No access to NGS? No bandwidth to keep pace with incoming volumes or implement a new assay ? No problem.

SOPHiA DDM™ Integrated Access Mode lets you tap into certified sequencing partners and a library of >50 applications covering key biomarkers in oncology and rare disorders. Our partners generate the sequencing data then securely upload it to your SOPHiA DDM™ account for analysis and reporting. You maintain full ownership of all data.

### KEY BENEFITS



#### ACCURACY

Access to robust NGS-based genomic applications, regardless of your expertise



#### EFFICIENCY

Accelerate your research and publish sooner as you gain top analytical performance



#### SECURITY

Keep control of and access to your data

## How SOPHiA DDM™ Integrated Access Mode works



### WANT TO KNOW MORE ?

Contact us at [info@sophiagenetics.com](mailto:info@sophiagenetics.com)

\*SOPHiA DDM™ is compliant with HIPAA, GDPR, and other local regulations.

## >50 APPLICATIONS AVAILABLE

Choose from single-gene to disease-specific applications and beyond.



Blood Cancers

Solid Tumors

Hereditary Cancers



Cardiology

Metabolism

Neurology

Pediatric

#### FLAGSHIP APPLICATIONS

##### TARGETED

- Minimal Residual Disease (MRD)<sup>†</sup>
- Homologous Recombination Deficiency (HRD)
- RNA Fusion Detection
- Liquid biopsy

##### LARGE

- Pan Cancer
- Comprehensive Genomic Profiling (CGP)

#### FLAGSHIP APPLICATIONS

##### TARGETED

- Disease-specific
- Expertly-designed
- Pharmacogenomics

##### LARGE

- Clinical Exome
- Whole Exome
- Whole Genome<sup>†</sup>

### Including lab-backed applications

#### MSK-ACCESS<sup>®</sup>

Design and validation results published in **Nature Communications**<sup>1</sup>

#### MSK-IMPACT<sup>®†</sup>


>900 publications by MSK investigators<sup>2</sup>

#### SureSelect Cancer CGP Assay

Pan-cancer profiling

1. Brannon AR, et al. Nat. Commun. 2021 Jun 18;12(1):3770; 2. Data provided by MSK - accurate as of April 2024

## >10 CERTIFIED PARTNERS WORLDWIDE



### About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.

© 2024 SOPHiA GENETICS. All rights reserved.

<sup>†</sup>Market availability requires approval under local regulations. Technology and concepts in development, may not be available for sale.

